$BRTX
BioRestorative Therapies, Inc. Stock $brtx

$brtx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223016630 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$64.50K	$31.30K	$16.00K
YoY Change	-9.28%	95.63%	-11.11%
Cost Of Revenue
YoY Change
Gross Profit	$64.50K
YoY Change
Gross Profit Margin	100.0%
Selling, General & Admin	$2.213M	$4.299M	$4.294M
YoY Change	-38.94%	0.11%	-71.19%
% of Gross Profit	3431.26%
Research & Development	$967.9K	$1.511M	$775.3K
YoY Change	-9.98%	94.91%	369.19%
% of Gross Profit	1500.61%
Depreciation & Amortization	$41.53K	$39.35K	$26.01K
YoY Change	31.76%	51.29%	7.48%
% of Gross Profit	64.39%
Operating Expenses	$3.181M	$5.810M	$5.070M
YoY Change	-32.31%	14.61%	-66.36%
Operating Profit	-$3.117M	-$5.779M	-$5.054M
YoY Change	-32.67%	14.35%
Interest Expense	$96.19K	$18.22K	-$29.01K
YoY Change	-306.37%	-162.81%	-95.15%
% of Operating Profit
Other Income/Expense, Net	$136.0K	$94.88K	$16.65K
YoY Change	-391.76%	469.83%
Pretax Income	-$2.981M	-$5.684M	-$4.816M
YoY Change	-36.25%	18.02%	-69.23%
Income Tax
% Of Pretax Income
Net Earnings	-$2.981M	-$5.700M	-$4.816M
YoY Change	-36.25%	18.35%	-69.23%
Net Earnings / Revenue	-4621.01%	-18210.86%	-30100.94%
Basic Earnings Per Share	-$0.77	-$1.53	-$1.37
Diluted Earnings Per Share	-$0.77	-$1.53	-$1.367M
COMMON SHARES
Basic Shares Outstanding	3.888M shares	3.768M shares	3.523M shares
Diluted Shares Outstanding	3.886M shares	3.717M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.62M	$12.37M	$19.32M
YoY Change	-35.23%	-35.96%	672.62%
Cash & Equivalents	$1.784M	$1.836M	$19.32M
Short-Term Investments	$9.832M	$10.54M
Other Short-Term Assets	$403.6K	$393.1K	$540.3K
YoY Change	7.76%	-27.25%	616.08%
Inventory
Prepaid Expenses
Receivables	$25.00K	$16.00K	$16.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$12.04M	$12.78M	$19.88M
YoY Change	-34.27%	-35.69%	666.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$314.1K	$304.1K	$469.0K
YoY Change	17.74%	-35.16%	1.69%
Goodwill
YoY Change
Intangibles	$758.6K	$781.0K
YoY Change	37.74%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.256M	$1.298M	$1.040M
YoY Change	12.45%	24.78%	-6.03%
TOTAL ASSETS
Total Short-Term Assets	$12.04M	$12.78M	$19.88M
Total Long-Term Assets	$1.256M	$1.298M	$1.040M
Total Assets	$13.30M	$14.08M	$20.92M
YoY Change	-31.59%	-32.69%	465.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$276.0K	$92.59K	$213.9K
YoY Change	-27.02%	-56.71%	-12.93%
Accrued Expenses	$386.3K	$233.0K	$279.9K
YoY Change	236.93%	-16.77%	-72.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$812.9K	$470.4K	$493.8K
YoY Change	30.73%	-4.75%	-61.77%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$83.58K	$123.5K	$268.4K
YoY Change	-64.29%	-53.96%	-31.59%
Total Long-Term Liabilities	$83.58K	$123.5K	$268.4K
YoY Change	-64.29%	-53.96%	-94.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$812.9K	$470.4K	$493.8K
Total Long-Term Liabilities	$83.58K	$123.5K	$268.4K
Total Liabilities	$896.4K	$593.9K	$762.2K
YoY Change	4.74%	-22.08%	-88.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$161.3M	-$158.3M
YoY Change	12.33%
Common Stock	$399.00	$378.00
YoY Change	9.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$12.40M	$13.49M	$20.16M
YoY Change
Total Liabilities & Shareholders Equity	$13.30M	$14.08M	$20.92M
YoY Change	-31.59%	-32.69%	465.2%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$2.981M	-$5.700M	-$4.816M
YoY Change	-36.25%	18.35%	-69.23%
Depreciation, Depletion And Amortization	$41.53K	$39.35K	$26.01K
YoY Change	31.76%	51.29%	7.48%
Cash From Operating Activities	-$1.130M	-$2.300M	-$1.595M
YoY Change	-9.66%	44.23%	95.97%
INVESTING ACTIVITIES
Capital Expenditures	$29.05K	$60.02K	-$109.6K
YoY Change	-121.1%	-154.78%
Acquisitions
YoY Change
Other Investing Activities	$694.9K	$2.569M
YoY Change
Cash From Investing Activities	$665.8K	$2.509M	-$109.6K
YoY Change	-583.59%	-2389.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	411.7K
YoY Change
NET CHANGE
Cash From Operating Activities	-1.130M	-$2.300M	-1.595M
Cash From Investing Activities	665.8K	$2.509M	-109.6K
Cash From Financing Activities	411.7K
Net Change In Cash	-52.83K	$159.9K	$0.00
YoY Change	-96.2%
FREE CASH FLOW
Cash From Operating Activities	-$1.130M	-$2.300M	-$1.595M
Capital Expenditures	$29.05K	$60.02K	-$109.6K
Free Cash Flow	-$1.159M	-$2.360M	-$1.485M
YoY Change	4.13%	58.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001505497
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	BRTX	Grant Income GrantIncome		usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2023Q1	BRTX	Gain On Ppp Loan Forgiveness GainOnPppLoanForgiveness		usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-37603
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	BIORESTORATIVE THERAPIES, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-1341024
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	40 Marcus Drive
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Melville
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11747
CY2023Q1	dei	City Area Code CityAreaCode	(631)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	760-8100
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	BRTX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Bankruptcy Proceedings Reporting Current EntityBankruptcyProceedingsReportingCurrent	true
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3887615	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1836469	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1676577	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	10537580	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	13072831	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	393054	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	363082	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	12783103	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	15128490	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	304110	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	261003	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	212749	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	241760	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	781002	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	803438	usd
CY2023Q1	us-gaap	Assets Assets	14080964	usd
CY2022Q4	us-gaap	Assets Assets	16434691	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	92586	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	170902	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	232984	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	130072	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	144821	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	139328	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	470391	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	440302	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	123536	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	162317	usd
CY2023Q1	us-gaap	Liabilities Liabilities	593927	usd
CY2022Q4	us-gaap	Liabilities Liabilities	602619	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3767615	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3677775	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3677775	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	378	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	369	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	171796596	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	168457418	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-158325119	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152640897	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	13487037	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	15832072	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14080964	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16434691	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31300	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1511245	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	775337	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4299153	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4294456	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	5810398	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	5069793	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5779098	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5053793	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	18216	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-29011	usd
CY2022Q1	BRTX	Gain On Ppp Loan Forgiveness GainOnPppLoanForgiveness	250000	usd
CY2022Q1	BRTX	Grant Income GrantIncome	16654	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	76660	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	94876	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	237643	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5684222	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4816150	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.53
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.37
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3717472	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3523202	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	15832072	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1148759	usd
CY2023Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	2190428	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5684222	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	13487037	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	21596949	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1164135	usd
CY2022Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	2138949	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	72819	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4816150	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	20156702	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5684222	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4816150	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	39351	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26011	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	33403	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3339187	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3375903	usd
CY2022Q1	BRTX	Gain On Ppp Loan Forgiveness GainOnPppLoanForgiveness	250000	usd
CY2023Q1	BRTX	Noncash Lease Expense NoncashLeaseExpense	29011	usd
CY2022Q1	BRTX	Noncash Lease Expense NoncashLeaseExpense	29011	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	29972	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	104099	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-78316	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	163067	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	102912	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	21067	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-33288	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-28444	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2348740	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1594634	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2568654	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	60022	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	109573	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2508632	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-109573	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	159892	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1704207	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1676577	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21026727	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1836469	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19322520	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5700000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3300000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2300000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zQyiBj9Owypf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_868_zDYql6VpZB9j">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at the date of the condensed consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ from these estimates which may cause the Company’s future results to be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zMRh8ek1ejCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_862_zoAXBTWcyxl6">Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution. The Company maintains deposits in its cash account in excess of the Federal Depository Insurance Corporation coverage of $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20230331_zCsu5B7OmS41" title="FDIC insured limit">250,000</span>. As of March 31, 2023, the Company has not experienced losses on this account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The royalties related to the Company’s sublicense comprised all of the Company’s revenue during the three months ended March 31, 2023 and 2022.</span></p>
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	144821	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	123899	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	123536	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	268357	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	10537580	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	13072831	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7900716	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7368061	shares
CY2022Q4	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	175000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	803438	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22436	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	781002	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	162500	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	26250	usd
CY2023Q1	BRTX	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	70484	usd
CY2022Q4	BRTX	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	103822	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	232984	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	130072	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	629017	shares
CY2023Q1	BRTX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue	1745000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	25000	shares
CY2022Q1	BRTX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue	122117	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	864639	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.08
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	629017	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.91
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1493656	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.17
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	951222	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.62
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3339187	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3375903	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	3766772	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3339187	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3375903	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	42007	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	40783	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	42007	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	40783	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	42007	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	40783	usd
CY2023Q1	BRTX	Operating Lease Liability Reduction OperatingLeaseLiabilityReduction	33288	usd
CY2022Q1	BRTX	Operating Lease Liability Reduction OperatingLeaseLiabilityReduction	28444	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	212749	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	328794	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	169286	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	129795	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	299081	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	30724	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	268357	usd

Files In Submission

Name	View Source	Status
brtx-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
brtx-20230331_pre.xml	Edgar Link	unprocessable
0001493152-23-016630-index-headers.html	Edgar Link	pending
0001493152-23-016630-index.html	Edgar Link	pending
0001493152-23-016630.txt	Edgar Link	pending
0001493152-23-016630-xbrl.zip	Edgar Link	pending
brtx-20230331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
brtx-20230331_def.xml	Edgar Link	unprocessable
brtx-20230331_cal.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRTX
BioRestorative Therapies, Inc. Stock $brtx

2023 Q2 Form 10-Q Financial Statement

#000149315223016630 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX BioRestorative Therapies, Inc. Stock $brtx

2023 Q2 Form 10-Q Financial Statement

#000149315223016630 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX
BioRestorative Therapies, Inc. Stock $brtx